In cancer immunotherapy, antibodies that interfere with the functions of immune checkpoint molecules such as Programmed cell death-1 (PD-1, encoded by Pdcd1) and Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are administered to cancer patients. The gene discussed is PDCD1; the disease is cancer.